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ABSTRACT
Pregnant women are at risk of severe and complicated influenza, and so are children aged 2-5 years. Despite numerous 
recommendations, influenza vaccination coverage in pregnant women is still low. The trigger for this article was the devel-
opment of new quadrivalent influenza vaccines along with the publication of new studies on the safety and effectiveness 
of inactivated influenza vaccines in pregnant women, administered also in the first trimester of pregnancy. The inactivated 
quadrivalent influenza vaccine is a safe and effective measure for preventing influenza in both mother and child. Live at-
tenuated influenza vaccines are contraindicated in pregnant women, whereas inactivated influenza vaccines should be 
recommended to all pregnant women, either healthy or with comorbidities. Influenza vaccines can be administered dur-
ing any pregnancy trimester, at least two weeks before delivery. The time of vaccination depends on vaccine availability; 
however, it should not be postponed unless there are significant medical contraindications.
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INTRODUCTION
According to the World Health Organization (WHO), 
5–10% of the adult population and 10–20% of the children 
population become ill with influenza seasonally, and as 
many as 600,000 patients die of influenza or its complica-
tions globally [1]. Groups exposed to severe and complicat-
ed influenza involve children aged 2–5 years, senior citizens 
aged > 65, patients with chronic diseases (e.g. respiratory, 
circulatory, nervous and metabolic diseases) and pregnant 
women [1]. Observations made during the 20th century in-
fluenza pandemics show that pregnant women experience 
more severe influenza than the general population, and 
they are at a higher risk of complications, hospitalization 
(including intensive care treatment) and death [2]. During 
the Spanish flu pandemic, mortality in pregnant women 
was estimated at 27–45%, whereas the number of deaths 
during the influenza pandemic in 1957 and 1968 reached 
70,000 and 30,000, respectively, whereby nearly half of the 
deaths were reported in pregnant women [2]. During the 
last influenza pandemic of 2009, the risk of influenza hos-
pitalization in pregnant women with comorbidities was 
7–8 times higher compared to the general population; the 
risk of complications was higher in the second and third 
trimester and the postpartum period (up to two weeks after 
the delivery), and as many as 5% of all deaths related to the 
influenza pandemic in the USA were reported in pregnant 
women [3–6].
A systematic review of 100 studies showed that the 
percentage of pregnant women hospitalized for influenza 
ranged from 5% to 87%, 0–22% of whom required intensive 
care treatment [4].
Recommendations for influenza vaccination during 
pregnancy were first published by the American Advisory 
Committee on Immunization Practices (ACIP) in 1997, and 
then extended in 2004 with a recommendation for influenza 
vaccinations in the first trimester [7]. Since 2005, the World 
Health Organization has been recommending vaccination 
for all pregnant women in a given influenza season [1]. In-
fluenza vaccination during pregnancy is also recommended 
by the American College of Obstetricians and Gynecolo-
gists (ACOG) [8]. The Polish Immunization Schedule includes 
recommendations for influenza vaccinations in pregnant 
women and those planning pregnancy [9]. However, despite 
numerous recommendations, influenza vaccination cover-
age in pregnant women is still low in many low and middle 
income countries as well as many developed countries, 
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which can be related to vaccine safety concerns of patients 
and medical workers, neglect of the disease severity and 
underestimation of the benefits of vaccination [7, 8].
The trigger for this publication was the development of 
new quadrivalent influenza vaccines along with new study 
results that have confirmed the effectiveness and safety of 
inactivated influenza vaccines in pregnant women (also in 
the first trimester).
Why ARe pRegNANT WOMeN expOSeD TO 
SeveRe AND COMplICATeD INflUeNzA?
Influenza incidence in pregnant women is the same as 
in the general population; however, disease severity and 
the risk of death in this group are higher [2–6]. The reason 
behind this phenomenon are changes in the immune sys-
tem during pregnancy, such as impaired cellular immunity, 
which is crucial for combating viral infections [10]. Other 
changes that can be observed are related to humoral im-
munity, which is why during the influenza A (H1N1) pan-
demic of 2009, pregnant women with H1N1 influenza virus 
infection showed lower serum IgG2 levels compared to the 
infected non-pregnant women, and thus they were exposed 
to abnormal cytokine production and more severe and 
complicated influenza [10]. Influenza complications dur-
ing pregnancy are often related to lung function changes 
(reduced lung capacity and reduced tidal volume), as well as 
hemodynamic changes in the circulatory system (increased 
cardiac output, increased oxygen consumption) [5, 10].
INflUeNzA COMplICATIONS 
IN MOTheR AND ChIlD
The most frequently reported maternal influenza com-
plications include pneumonia and acute respiratory failure, 
which requires respiratory support, mechanical ventilation, 
or even ECMO [10]. Influenza during pregnancy has been 
reported to increase the risk of premature delivery (with 
all its consequences), miscarriage, intrauterine fetal death, 
and low birth weight, whereas maternal fever may cause 
fetal tachyarrhythmias [10–14]. During the 2009 influenza 
pandemic, it was observed that influenza during pregnancy 
increased the risk of fetal death or neonatal death, as well 
as the likelihood of cesarean section delivery [15–17]. The 
tragic effects of influenza during pregnancy (including 
mother’s or newborn’s death) have also been reported in 
Polish scientific literature [13]. 
It should be emphasized that newborns and infants 
are at risk of severe and complicated influenza. Although 
influenza infections in newborns are rarely reported, recent 
studies have indicated vertical transmission as a route of in-
fluenza transmission, besides droplet and contact transmis-
sion [17]. In a group of children with influenza under the age 
of 12 months, 4% required mechanical ventilation support 
and 10% required intensive care treatment (hospitalization 
risk was higher in children aged < 3 months as compared 
to those aged 6–12 months) [18].
INflUeNzA pReveNTION 
IN pRegNANT WOMeN
Non-specific influenza prevention measures in pregnant 
women include hand hygiene, the so-called “cough etiquette” 
and avoiding crowded places. Pre- and post-exposure phar-
macological prophylaxis with neuraminidase inhibitors is 
also recommended [2, 4]. The only registered drug available 
on the Polish market is oseltamivir for oral administration 
(zanamivir for inhalation is registered but not available). 
However, it needs to be clearly stated that oseltamivir should 
be primarily used for the causal treatment of influenza and 
must not be abused in influenza prophylaxis due to the risk 
of developing drug resistance, and furthermore, it can cause 
adverse effects (mostly associated with the digestive system) 
as any other drug, which is why its effectiveness in influenza 
prevention is estimated at 80% [19].
The most important measure of preventing influenza in 
pregnant women is vaccination. Currently, split vaccines and 
subunit vaccines are recommended in this risk group, both 
administered intramuscularly or subcutaneously [7, 8]. Live 
attenuated influenza vaccines for intranasal administration 
are contraindicated during pregnancy [7, 8].
INflUeNzA vACCINe SAfeTy IN pRegNANCy
Data on inactivated vaccines for seasonal influenza in-
dicate that they are safe for both mother and child. A ret-
rospective observational study by Nordin et al., conducted 
on a group 79,900 vaccinated and 148,000 unvaccinated 
pregnant women, showed that there was no increased risk 
of adverse vaccination reactions within 42 days after the 
vaccination [20]. Approximately 2.4 million pregnant women 
were vaccinated against influenza in the US in the 2009–
2010 season, and no increased risk to mother or child was 
shown [20]. A detailed systematic review on influenza vac-
cine safety in pregnancy showed that inactivated influenza 
vaccines do not increase the risk of intrauterine fetal death, 
spontaneous miscarriage or the occurrence of birth defects 
in a child [21]. Data on the safety of influenza vaccines in 
pregnancy refer to inactivated vaccines with split virion or 
sub-unit vaccines without adjuvants (these vaccines are 
available in Poland). Currently, there is not enough data on 
the safety of adjuvanted vaccine, such as MF59 (squalene 
oil-based adjuvant used since 1997) and AS03 (a combina-
tion of tocopherol and squalene in an oil-in-water emul-
sion used during the 2009 pandemic), so as to recommend 
them for pregnant women [7, 8]. One retrospective study 
conducted on a group of pregnant women showed a higher 
incidence of gestational diabetes and eclampsia among 
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women who were administered an MF59 adjuvanted influ-
enza vaccine [22]. In a randomized, controlled clinical trial 
comparing the MF59-adjuvanted vaccine in pregnant and 
non-pregnant women, a negligible tendency for a lower im-
mune response was observed in pregnant women; 72% of 
women reported adverse reactions, 64% had local reactions 
and 26% had systemic reactions, the most common symp-
tom being malaise [23]. AS03-adjuvanted influenza vaccine, 
which was administered to approximately 380,000 pregnant 
women, was associated with an increased risk of narcolepsy 
in children, which shows that oil emulsion-based adjuvants 
are not fully safe in less studied patient populations, such 
as children and pregnant women [24].
The number of studies on the effectiveness of vaccines 
based on recombinant hemagglutinin protein that is pro-
duced in insect cells (intended for American adults allergic to 
chicken egg protein) is also insufficient so as to recommend 
these vaccines for pregnant women [3].
Studies performed after the 2009 influenza pandemic 
have confirmed the safety of inactivated vaccines against 
influenza in pregnant women. In a randomized trial from 
the USA, Munoz et al. proved that two inactivated trivalent 
seasonal influenza vaccines are safe [21]. In an Australian co-
hort, no evidence on the increased occurrence of adverse 
reactions was found in vaccinated pregnant women as com-
pared to non-pregnant women [25].
Recently, increasingly more scientific reports proving 
influenza vaccine safety in the first trimester have been 
published.
The effect of influenza vaccination on pregnancy and 
fetal development was assessed by Japanese researchers in 
the 2013/2014 season [26]. The following endpoints were 
considered: miscarriage, fetal death, preterm delivery, low 
birth weight and birth defects. Adverse delivery outcomes 
were reported for 641 (10%) of 6,387 unvaccinated pregnant 
women and 356 (9%) of 3,943 vaccinated pregnant women. 
Even considering potential confounding factors, vaccina-
tions during pregnancy were not associated with a risk of 
adverse delivery outcomes (odds ratio 0.90, 95% confidence 
interval 0.76–1.07). Vaccinations in the first or second trimes-
ter showed no association with adverse delivery outcomes, 
while vaccination in the third trimester was associated with 
a reduced risk of adverse delivery outcomes (odds ratio 
0.70, 95% confidence interval 0.51–0.98) [26]. Similar con-
clusions regarding the performance of vaccinations in the 
first trimester were also made by American researchers in 
a study from 2004–2013 [27]. A total of 52,856 children 
of vaccinated mothers were assessed with regard to their 
psychomotor development in the first 12 months of life and 
compared with 373,088 children of mothers who were not 
vaccinated in the first trimester. The incidence of structural 
birth defects (per 100 live births) was 1.6 in the group of 
children of vaccinated mothers compared to 1.5 in the group 
of children of unvaccinated mothers (corrected PR of 1.02, 
95% CI 0.94–1.10) [27].
effeCTIveNeSS Of INflUeNzA 
vACCINATIONS IN pRegNANCy
The immunogenicity of influenza vaccines in pregnant 
women is comparable to that observed in non-pregnant 
women (i.e. the post-vaccination level of antibodies is com-
parable). Similar results were observed in the 1970s in the 
studies on A/New Jersey/8/76 monovalent vaccine, which 
showed no reduction in the number of vaccine antibodies 
in pregnant women compared to the general population [2]. 
During the 2009 pandemic, it was confirmed that the in-
activated monovalent H1N1/2009pdm vaccine was immu-
nogenic in pregnant women, although women who had 
previously been administered a seasonal vaccine showed 
a lower seroprotection rate [28].
The actual effectiveness of influenza vaccines during 
pregnancy has also been proven, along with vaccination 
benefits for both mother and child.
A randomized clinical trial entitled “Mother’s Gift”, 
which was conducted in Bangladesh by Zamana et al. [29] 
in 2004–2005, focused on the effectiveness of influenza 
vaccinations in the third trimester and the obtained results 
were compared with the numbers related to pneumococ-
cal polysaccharide vaccinations (control group) [29]. It was 
found that the number of laboratory confirmed influenza 
cases decreased by 63% in children of mothers who were 
vaccinated during pregnancy (this effect was observed dur-
ing the first 6 months of the child’s life) [29]. Vaccinations in 
the third trimester resulted in a reduced number of infec-
tions with fever by 29% in infants and 36% in mothers [29].
Protective antibody levels were maintained in infants for 
6 months, with an estimated half-life of 42–50 days. A higher 
level of IgA antibodies was also found in the breast milk of 
influenza-vaccinated pregnant mothers for 6 months [29].
A clinical study conducted by Thompson et al. [30] in 
two influenza seasons 2010–2012 showed that influenza 
vaccinations in pregnant women reduced the risk of acute 
respiratory symptoms associated with laboratory-confirmed 
influenza by approx 50%.
A quadrivalent influenza vaccine has been available 
since 2012, and it has replaced the trivalent vaccine. This 
vaccine contains two influenza A virus subtypes and two cur-
rently circulating influenza B virus strains (Victoria and Yama-
gata), whereas the trivalent vaccine contains only one of the 
influenza B virus strains. To assess the actual effectiveness 
of the quadrivalent inactivated split vaccine, a randomized, 
actively controlled blinded study on a group of 4,193 preg-
nant women in the third trimester was conducted in Mali 
from September 2011 to April 2013 [31]. The study involved 
632
Ginekologia Polska 2020, vol. 91, no. 10
www. journals.viamedica.pl/ginekologia_polska
weekly medical visits, during which infants up to 6 months 
of age were tested for an influenza-like disease, and RT-PCR 
tests were made to identify laboratory-confirmed influenza 
[31]. The primary objectives of the study included: 1. Assess-
ment of the effectiveness of the vaccine against the first 
laboratory-confirmed influenza episode in infants born to 
women vaccinated at any time before delivery; 2. Assess-
ment of the effectiveness of the vaccine against the first 
laboratory-confirmed influenza episode in infants born to 
women vaccinated ≥ 14 days before delivery. The second-
ary purpose of the study was assessment of the effective-
ness of the vaccine against the first laboratory-confirmed 
influenza episode in women (before and after delivery) 
[31]. Infants aged < 6 months, whose mothers had been 
vaccinated at any time during pregnancy, showed vaccina-
tion effectiveness of 33.1% (95% CI 3.7–53.9%), whereby 
the effectiveness against laboratory-confirmed influenza in 
the first 4 months of life was 67.9% (95% CI 35.1–85.3%). In-
fants < 6 months whose mothers were vaccinated ≥ 14 days 
before the delivery showed vaccine effectiveness of 37.3% 
(95% CI 7.6–57.8%); however, during the first 4 months of 
life the effectiveness was higher and reached 70.2% (95% CI 
35.7–87.6%). Vaccine effectiveness in preventing laborato-
ry-confirmed influenza in vaccinated women was estimated 
at 70.3% (95% CI 42.2–85.8%) [31].
The benefits of vaccinating pregnant women can be 
observed in the first six months of child’s life. Since the 
influenza vaccine can be administered from the age of six 
months, infants cannot be vaccinated. Due to the functional 
immaturity of their immune system, infants, especially those 
aged > 6 months, suffer from influenza more frequently and 
are five times more likely to be hospitalized, as compared 
to infants aged 6–23 months [22].
In the light of the above statistics, a mother’s vaccina-
tion protects a child who can become ill with influenza but 
is too young to be vaccinated. Vaccination results in the 
production of maternal antibodies which are transmitted 
to the child transplacentally and in breast milk. The degree 
and duration of the child protection are related to the level 
of maternal influenza antibody titers, which in turn depends 
on the time interval between vaccination and delivery [32]. 
How long the passively acquired antibodies persist in in-
fants, it depends on their initial concentration in the um-
bilical cord blood; however, it is no longer than 6 months 
[32]. The effect of a mother’s vaccination on a child has 
been evaluated in many studies. In a controlled compara-
tive study from 2000–2009 (before H1N1 2009 pandemic), 
there were 90% fewer influenza-related hospitalizations 
in a group of infants aged < 6 months and born to influ-
enza vaccinated mothers than in the group of children of 
non-vaccinated mothers [33]. Since no seroprotection was 
observed in children of mothers who had been vaccinated 
only 15 days before delivery, it can be assumed that vaccina-
tion against influenza should be performed at least 2 weeks 
before delivery to maximize the neonatal protection [33]. 
In a UK study, a mother’s vaccination during pregnancy in 
the 2013/2014 season was effective for 71% infants under 
6 months of age [34].
WheN TO geT vACCINATeD?
Influenza vaccination with an inactivated vaccine can be 
performed in any pregnancy trimester. In order to obtain 
optimal protection against influenza in both mother and 
child, it is recommended to perform a vaccination at least 
2 weeks before the planned delivery. Later vaccination is 
safe but might not be effective enough (time between the 
production of antibodies and their transplacental transfer 
is too short). However, it should be emphasized that vac-
cination in this time is still beneficial and so is vaccination 
in the postpartum period, as part of the cocoon strategy. 
The strategy involves vaccinating people in the immediate 
environment of a patient (the newborn) who may become 
ill but cannot be vaccinated (because of being too young). 
Being part of the cocoon strategy, vaccinations in the im-
mediate environment reduce the transmission of pathogens 
and the risk of becoming ill [35].
For many years, influenza vaccinations were recom-
mended only when the vaccine composition recommended 
for a given season was available (most often in September). 
However, it should be emphasized that influenza vacci-
nation can and should be performed during any autumn 
or winter month when there is increased influenza virus 
circulation. Postponement of the vaccination, caused e.g. 
by a delay in the vaccine development (which took place 
previously and was caused e.g. by the delay in the publica-
tion of the WHO vaccine composition recommendations 
for a given season or technological/production difficulties) 
does not adversely affect the effectiveness of vaccination. 
Furthermore, it can have a positive aspect. Antibodies have 
been shown to persist for up to 6 months and gradually 
disappear after the vaccination, which is why early vac-
cination may result in low levels of antibodies at the end of 
the influenza season [35]. In the case of patients at risk (e.g. 
patients with chronic respiratory, circulatory and metabolic 
diseases), vaccination is currently not recommended at the 
beginning of the season but later to ensure high antibody 
level throughout the influenza season [35]. 
CONClUSIONS
Inactivated quadrivalent influenza vaccine is a safe and 
effective measure for preventing influenza in mothers and 
children. It can be recommended to all pregnant women, 
who are healthy or have comorbidities. The vaccine can be 
administered in any pregnancy trimester. The time of vac-
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cination depends on the vaccine availability; however, it 
should not be postponed unless there are significant medi-
cal counterindications.
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